FDA Developing Guidance On Rational Development Of Combined Novel Drugs
Executive Summary
FDA is developing guidances -both in general and for specific therapeutic areas - for co-development of investigational drugs intended to be used in combination, and the move is indeed timely.
You may also be interested in...
FDA Draft Co-Development Guidance Emphasizes Phase II Studies
Clinical trial strategies proposed in FDA's draft guidance for co-development of drugs designed for use in combination in most cases whittle the design down to standard of care versus the combination before Phase III, offering the prospect of cutting not only development time but also clinical trial costs.
FDA Draft Co-Development Guidance Emphasizes Phase II Studies
Clinical trial strategies proposed in FDA's draft guidance for co-development of drugs designed for use in combination in most cases whittle the design down to standard of care versus the combination before Phase III, offering the prospect of cutting not only development time but also clinical trial costs.
FDA Issues Co-Development Guidance, But Only For Products Treating "Serious" Diseases
FDA Commissioner Hamburg and CDER Director Woodcock outline the requirements for developing drugs in combination during the Faster Cures Partnering for Cures meeting in New York.